Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFα-based isolated limb perfusion

In Vivo

Volumn 23, Issue 2, 2009, Pages 347-352

  di Filippo, F ^a   Giacomini, P ^a   Rossi, C R ^b   Santinami, M ^c   Anza M ^a   Garinei, R ^a   Perri, P ^a   Botti, C ^a   di Angelo, P ^a   Sofra, C ^a   Pasqualoni, R ^a   Sperduti, I ^a   Cavaliere, F ^d   di Filippo, S ^a   Corrias, F ^a   Armenti, A ^a   Ferraresi, V ^a   Ginebri, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

In transit metastases; Melanoma; Prognostic factors; Regional perfusion; TNF

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IN-TRANSIT METASTASIS; LIMB DISEASE; LIMB PERFUSION; LIMB TOXICITY; LIMB TUMOR; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; REGIONAL PERFUSION; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; EXTREMITIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; PERFUSION; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64549127738     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Balch CM, Soong SI, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMaasters KM, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhand Y, Liu PY and Lyman GH: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001.
2. Creech O Jr, Krementz ET, Ryan RF and Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616-632, 1958.
3. Di Filippo F, Anzà M, Rossi CR, Cavaliere F, Botti C, Lise M, Garinei R, Giannarelli D, Vasselli S, Zupi G and Cavaliere R: The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 14: 215-223, 1998.
4. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F and Lejeune FJ: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9(5): 491-502, 1999.
5. Di Filippo F, Rossi CR, Garinei R, Anzà M, Cavaliere F, Botti C, Perri P, Di Filippo S, Di Angelo P, Principi F and Laurenzi L: Hyperthermic antiblastic perfusion with TNFα and melphalan in stage III limb melanoma patients: A Phase I-II SITILO Study. J Exp Clin Cancer Res 22(4): 97-101, 2003.
6. Smith J: Histopathology and Biological Behavior of Melanoma, Neoplasms of the Skin and Malignant Melanomas. Chicago: Year Book Medical Publishers, 1976.
7. Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F and Cavaliere R: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63: 2551-2561, 1989.
8. Casara D, Rubello D, Pilati PP, Scalerta R, Foletto M and Rossi CR: Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand-held gamma probe and 99mTc-HAS. Nucl Med Commun 25(1): 61-66, 2004.
9. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA and Olthuis GA: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reaction. Eur J Cancer Clin Oncol 18(10): 905-910, 1982.
10. WHO: WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
11. Kaplan EL and Meier P: Non-parametric estination from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
12. Cox DR: Regression models and life tables. J Royal Stat Soc 4: 187-200, 1972.
13. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel B, Eggermont AM and Kroon BB: Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139(11): 1237-1242, 2004.
14. Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH and Eggermont AM: One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240(6): 939-947; discussion 947-948, 2004.
15. Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL and Alexander HR: Factors affecting survival after complete response to isolated limb perfusion in patients with intransit melanoma. Ann Surg Oncol 8(10): 771-778, 2001.
16. Fraker D, Alexander H and Ross M: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 9: S8, 2002.
17. Rossi CR, Foletto M, Mocellin S, Pilati PL and Lise M: Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-[alpha] and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11(2): 173-177, 2004.
18. Eggermont AM, de Wilt JH and ten Hagen TL: Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4: 429-437, 2003.
19. Di Filippo F, Rossi CR, Santinami M, Cavaliere F, Garinei R, Anzà M, Perri P, Botti C, Di Angelo P, Pasqualoni R and Di Filippo S: Hyperthermic isolation limb perfusion with TNFα in the treatment of in-transit melanoma metastasis. In Vivo 20: 739-742, 2006.
20. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL and Eggermont AM: Prerequisites for effective isolated limb perfusion using tumor necrosis factor alpha and melphalan in rats. Br J Cancer 8: 161-166, 1999.
21. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D and Lejeune FJ: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized Phase III trial. J Clin Oncol 16: 2906-2912, 1998.
22. Libutti SK, Alexander HR, Bartlett DL, Rosenberg SA and Fraker DL: Patterns of local failure in extremity melanoma after a complete response to isolated limb perfusion with Melphalan with or without tumor necrosis factor. Proc Am Soc Clin Oncol 15: 552, 1996.